BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32823550)

  • 1. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
    Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
    Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
    Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
    Chai TF; Manu KA; Casey PJ; Wang M
    Oncogene; 2020 Jul; 39(31):5373-5389. PubMed ID: 32561852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.
    Zhang Y; Lapidus RG; Liu P; Choi EY; Adediran S; Hussain A; Wang X; Liu X; Dan HC
    Mol Cancer Ther; 2016 Jul; 15(7):1504-14. PubMed ID: 27196761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement for epithelial p38α in KRAS-driven lung tumor progression.
    Vitos-Faleato J; Real SM; Gutierrez-Prat N; Villanueva A; Llonch E; Drosten M; Barbacid M; Nebreda AR
    Proc Natl Acad Sci U S A; 2020 Feb; 117(5):2588-2596. PubMed ID: 31969449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
    Seguin L; Kato S; Franovic A; Camargo MF; Lesperance J; Elliott KC; Yebra M; Mielgo A; Lowy AM; Husain H; Cascone T; Diao L; Wang J; Wistuba II; Heymach JV; Lippman SM; Desgrosellier JS; Anand S; Weis SM; Cheresh DA
    Nat Cell Biol; 2014 May; 16(5):457-68. PubMed ID: 24747441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A-kinase-interacting protein 1 promotes EMT and metastasis via PI3K/Akt/IKKβ pathway in cervical cancer.
    Zhang X; Liu S; Zhu Y
    Cell Biochem Funct; 2020 Aug; 38(6):782-791. PubMed ID: 32401379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
    Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma.
    Narita K; Matsuda Y; Seike M; Naito Z; Gemma A; Ishiwata T
    Int J Oncol; 2014 Apr; 44(4):1118-30. PubMed ID: 24481417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival.
    Nikou S; Arbi M; Dimitrakopoulos FD; Sirinian C; Chadla P; Pappa I; Ntaliarda G; Stathopoulos GT; Papadaki H; Zolota V; Lygerou Z; Kalofonos HP; Bravou V
    J Mol Histol; 2020 Aug; 51(4):385-400. PubMed ID: 32592097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
    Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
    Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation.
    Regala RP; Justilien V; Walsh MP; Weems C; Khoor A; Murray NR; Fields AP
    PLoS One; 2011; 6(10):e26439. PubMed ID: 22022614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.